Erik Alan Gustafson

US Patent:

7211570, May 1, 2007

Filed:

Dec 19, 2002

Appl. No.:

10/326444

Inventors:

Raymond F. Schinazi - Decatur GA, US
Junxing Shi - Duluth GA, US
Joyce D. Fingeroth - Sudbury MA, US
Erik Gustafson - Norwood MA, US

Assignee:

Pharmasset, Inc. - Princeton NJ
Emory University - Atlanta GA
Beth Israel Deaconess Medical Center - Boston MA

International Classification:

A61K 31/70
A01N 43/06
A01N 43/26
A01N 47/10
A01N 43/54

US Classification:

514 49, 514444, 514463, 514476, 514256

Abstract:

A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.

US Patent:

7527929, May 5, 2009

Filed:

Jul 29, 2005

Appl. No.:

11/194072

Inventors:

Kevin J. McKernan - Marblehead MA, US
Erik Gustafson - Norwood MA, US
Adrianne D. Brand - Wenham MA, US

Assignee:

Agencourt Bioscience Corporation - Beverly MA

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

The present invention is directed to a method of isolating a target species (e. g. , target nucleic acid species) from a mixture. In the methods of the present invention, the mixture is combined with solid phase carriers having a surface comprising multiple functional groups one of which reversibly and selectively binds the target species. In a particular embodiment, the mixture is combined with solid phase carriers having a first functional group which reversibly binds nucleic acids and a second functional group which selectively and reversibly binds the target nucleic acid species, thereby producing a first combination. The first combination is maintained under conditions appropriate for binding of the nucleic acids to the first functional group and binding of the target nucleic acid species to the second functional group. The solid phase carriers are separated from the first combination, and combined with an agent (e. g. , buffer) that selectively removes (e. g.

US Patent:

7638502, Dec 29, 2009

Filed:

Dec 4, 2006

Appl. No.:

11/633651

Inventors:

Raymond F. Schinazi - Decatur GA, US
Junxing Shi - Duluth GA, US
Joyce D. Fingeroth - Sudbury MA, US
Erik Gustafson - Norwood MA, US

Assignee:

Pharmasset, Inc. - Princeton NJ
Beth Israel Deaconess Medical Center - Boston MA
Emory University - Atlanta GA

International Classification:

A01N 43/04
A61K 31/70

US Classification:

514 50, 514 43, 514 49

Abstract:

A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.

US Patent:

8442924, May 14, 2013

Filed:

Nov 12, 2010

Appl. No.:

12/944992

Inventors:

Jiuliu Lu - Homestead FL, US
Zihua Wang - Newton MA, US
Antonio Arevalo Reyes - Middleton MA, US
Erik Alan Gustafson - Norwood MA, US
John Steven Riley - Miami FL, US

Assignee:

Beckman Coulter, Inc. - Brea CA

International Classification:

G06F 15/18

US Classification:

706 12

Abstract:

A method for determining the presence of a biological entity. The method may include entering into a digital computer, at least a plurality of first input values associated with a first genetic element (e. g. , mecA), a plurality of second input values associated with a second genetic element (femA), and a plurality of third input values associated with a third genetic element (e. g. , orfX) associated with a plurality of samples. Each sample includes a first input value in the plurality of first input values, a second input value in the plurality of second input values, and a third input value in the plurality of third input values. The method also includes determining a threshold value associated with the third genetic element, separating the samples using the threshold value into a first set of samples and a second set of samples, clustering the first set of samples in a feature space defined by the first genetic element and the second genetic element, defining a first boundary space using the first set of samples, and defining a second boundary space using the second set of samples. The first and second boundary spaces differentiate a biological entity from other biological statuses. Other embodiments may also include the use of a genetic element such as SCCmec.

US Patent:

20090191566, Jul 30, 2009

Filed:

Mar 3, 2009

Appl. No.:

12/396586

Inventors:

Kevin J. McKernan - Marblehead MA, US
Erik Gustafson - Norwood MA, US
Adrianne D. Brand - Wenham MA, US

Assignee:

AGENCOURT BIOSCIENCE CORPORATION - Beverly MA

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

The present invention is directed to a method of isolating a target species (e.g., target nucleic acid species) from a mixture. In the methods of the present invention, the mixture is combined with solid phase carriers having a surface comprising multiple functional groups one of which reversibly and selectively binds the target species. In a particular embodiment, the mixture is combined with solid phase carriers having a first functional group which reversibly binds nucleic acids and a second functional group which selectively and reversibly binds the target nucleic acid species, thereby producing a first combination. The first combination is maintained under conditions appropriate for binding of the nucleic acids to the first functional group and binding of the target nucleic acid species to the second functional group. The solid phase carriers are separated from the first combination, and combined with an agent (e.g., buffer) that selectively removes (e.g., elutes) either the nucleic acid from the first functional group or the target nucleic acid species from the second functional group of the solid phase carriers, thereby isolating a target nucleic acid species from a mixture comprising a plurality of nucleic acid species.

US Patent:

20100168052, Jul 1, 2010

Filed:

Dec 28, 2009

Appl. No.:

12/647959

Inventors:

Raymond F. Schinazi - Decatur GA, US
Junxing Shi - Duluth GA, US
Erik Gustafson - Norwood MA, US
Joyce D. Fingeroth - Sudbury MA, US

Assignee:

Pharmasset, Inc. - Princeton NJ
EMORY UNIVERSITY - Atlanta GA
BETH ISRAEL DEACONESS MEDICAL CENTER - Boston MA

International Classification:

A61K 31/7034
A61K 31/513
A61P 35/00
A61P 31/00
C12N 5/073

US Classification:

514 50, 514274, 435369

Abstract:

A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.

US Patent:

20120283957, Nov 8, 2012

Filed:

Nov 11, 2010

Appl. No.:

13/509347

Inventors:

Jiuliu Lu - Homestead FL, US
Zihua Wang - Newton MA, US
Antonio Arevalo Reyes - Middleton MA, US
Erik Alan Gustafson - Norwood MA, US
John Steven Riley - Miami FL, US

Assignee:

Beckman Coulter, Inc. - Brea CA

International Classification:

G06F 19/10
G06G 7/60
G06F 19/12
G06F 19/00

US Classification:

702 19, 703 11, 703 2

Abstract:

Systems and methods for identifying Methicillin resistant strains of (MRSA) in a sample are used that are based on the fact that an MRSA positive sample should have roughly the same copy numbers of mecA, SCCmec, and a -specific target gene sequence. The systems and methods may further present the three assays simultaneously on a 2-D plot with each axis of the plot 120 degrees apart. According to one embodiment, a Y plot is used for the 2-D display. If a given sample has similar readings of mecA, SCCmec, and a -specific target gene sequence, the sample's measured copy numbers of mecA, SCCmec, and the -specific target gene sequence can plot close to the origin regardless of the sample's absolute assay readings. With the help of this transformation, a boundary function can be defined that can be used to distinguish MRSA-positive samples from MRSA-negative samples.

US Patent:

20130196334, Aug 1, 2013

Filed:

Mar 29, 2013

Appl. No.:

13/853897

Inventors:

Beckman Coulter, Inc. - Brea CA, US
Zihua Wang - Newton MA, US
Antonio Arevalo Reyes - Middleton MA, US
Erik Alan Gustafson - Norwood MA, US
John Steven Riley - Miami FL, US

Assignee:

Beckman Coulter, Inc. - Brea CA

International Classification:

G06F 19/12
C12Q 1/68

US Classification:

435 612, 703 11

Abstract:

A method for determining the presence of a biological entity. The method may include entering into a digital computer, at least a plurality of first input values associated with a first genetic element, a plurality of second input values associated with a second genetic element, and a plurality of third input values associated with a third genetic element associated with a plurality of samples. The method also includes determining a threshold value associated with the third genetic element, separating the samples using the threshold value into a first set of samples and a second set of samples, clustering the first set of samples in a feature space defined by the first genetic element and the second genetic element, defining a first boundary space using the first set of samples, and defining a second boundary space using the second set of samples.